Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants

Table 4 Univariate analysis for the correlates of median local recurrence free, distant metastasis free and overall survival

	Local recurrence free survival (mo)			Distant metastasis free survival (mo)			Overall survival (mo)
	Before 2008 (n = 127)	2008-2010 (n = 74)	Total (n = 201)	Before 2008 (n = 127)	2008-2010 (n = 74)	Total (n= 201)	Before 2008 (n = 127)	2008-2010 (n = 74)	Total (n = 201)
Age
≤ 50 yr	44.1	20.6	49.8	14.0	23.1	14.0	28.7	20.6	33.7
> 50 yr	39.1	26.0	43.6	15.9	18.3	15.9	26.0	22.2	26.7
P value	0.066	0.471	0.312	0.747	0.925	0.48	0.044	0.65	0.181
Type of treatment
Chemoradiotherapy	37.8	24.1	37.8	11.7	19.2	11.7	31.9	24.1	31.9
Chemotherapy	43.6	22.3	51.7	15.0	18.2	15.3	25.9	20.6	27.1
P value	0.792	0.656	0.63	0.959	0.848	0.715	0.793	0.834	0.597
Type of gastrectomy surgery
Total	39.8	15.9	26.7	29.8	18.3	24.0	43.9	15.9	29.1
Subtotal	43.3	13.8	25.9	14.9	19.1	16.0	46.9	13.8	28.5
P value	0.885	0.122	0.888	0.395	0.636	0.393	0.318	0.1	0.092
Vascular involvement
No	49.7	11.5	39.7	26.0	-	26.0	49.8	11.5	43.9
Yes	35.0	16.0	23.5	24.0	18.3	21.4	37.8	16.2	24.0
P value	0.697	0.005	0.594	0.858	-	0.81	< 0.001	0.795	< 0.001
Perineural involvement
No	45.9	14.9	31.3	24.0	-	24.0	48.6	14.9	32.5
Yes	41.2	15.0	25.0	22.4	16.0	20.5	43.6	15.2	25.9
P value	0.706	0.353	0.822	0.609	-	0.999	0.122	0.275	0.058
T stage
T1	55.4	20.2	48.6	27.6	-	27.6	55.4	20.2	48.6
T2	54.4	16.4	28.3	29.4	30.2	29.8	54.4	16.9	32.4
T3	37.0	14.1	25.1	24.1	18.3	22.1	41.1	14.1	26.0
T4	30.9	24.4	24.4	18.6	12.6	16.6	31.8	30.6	30.6
P value	0.054	0.959	0.128	0.668	0.223	0.353	0.04	0.28	0.002
Nodal stage
N0	54.9	13.7	45.7	41.1	22.2	41.1	54.9	14.8	47.8
N1	46.9	14.6	29.1	30.6	21.0	27.7	53.7	14.8	37.0
N2	23.2	16.0	19.2	16.6	18.3	16.6	24.1	16.0	19.2
N3	27.1	13.4	16.6	16.1	12.6	15.0	35.0	13.4	20.7
P value	0.515	0.504	0.647	0.02	0.887	0.014	< 0.001	0.439	< 0.001
Nodal stage (AJCC 2002)
N0	54.9	11.3	42.1	41.1	22.2	41.1	54.9	11.3	45.7
N1	42.4	16.9	28.3	30.6	20.5	26.0	49.2	16.9	29.1
N2	19.3	15.5	16.1	14.2	13.8	14.2	20.1	15.5	19.1
N3	31.0	10.7	15.0	19.5	19.8	19.8	31.0	10.7	15.0
P value	0.057	0.283	0.024	0.011	0.817	0.001	< 0.001	0.224	< 0.001
LN1
< 15	40.5	14.9	30.5	24.0	19.1	23.1	45.7	14.9	33.2
> 16	42.7	15.0	25.4	24.0	18.3	20.5	44.9	15.2	25.7
P value	0.181	0.768	0.423	0.309	0.742	0.664	0.724	0.461	0.523
LN2
< 10	34.0	15.9	25.4	20.9	22.2	22.2	40.5	16.2	31.0
> 11	46.4	14.6	26.8	24.1	16.0	22.2	47.8	14.6	28.0
P value	0.169	0.768	0.373	0.204	0.742	0.349	0.985	0.464	0.822
Nodal stage (AJCC 2010)
N0	54.9	11.3	42.1	41.1	22.2	41.1	54.9	11.3	45.7
N1	51.0	16.9	39.1	29.4	36.8	33.1	53.8	16.9	44.9
N2	32.5	16.0	25.8	28.0	18.3	22.3	37.8	17.0	25.9
N3a	19.6	15.0	16.1	15.4	13.8	14.6	20.7	15.0	17.7
N3b	31.0	15.0	16.3	19.5	19.8	19.8	31.0	15.0	16.3
P value	0.131	0.402	0.057	0.06	0.849	0.039	< 0.001	0.098	< 0.001
Involved lymph nodes (n)
≤ 5	48.6	35.5	52.2	15.9	24.1	16.2	35.5	31.9	38.3
> 5	20.7	16.9	26.0	15.0	16.0	15.2	16.1	16.3	16.6
P value	0.002	0.564	< 0.001	0.036	0.191	0.218	0.23	0.001	< 0.001

AJCC: American Joint Commission on Cancer; LN: Lymph nodes.